- Home
- RVMD vs RPRX Comparison
RVMD vs RPRX Comparison
Compare RVMD & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | RPRX |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 19.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RVMD | RPRX |
|---|---|---|
| Price | $149.27 | $48.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | ★ $135.05 | $50.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.30 |
| Revenue Next Year | $411.49 | $4.80 |
| P/E Ratio | ★ N/A | $27.41 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $34.00 | $31.58 |
| 52 Week High | $148.00 | $49.06 |
Technical Indicators
Market Signals| Indicator | RVMD | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 86.84 | 59.82 |
| Support Level | $93.39 | $35.32 |
| Resistance Level | N/A | $49.06 |
| Average True Range (ATR) | 4.31 | 0.90 |
| MACD | 6.04 | 0.05 |
| Stochastic Oscillator | 96.35 | 76.33 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.